These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36244527)

  • 21. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
    Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
    J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.
    Jones JD; Sullivan MA; Manubay JM; Mogali S; Metz VE; Ciccocioppo R; Comer SD
    Physiol Behav; 2016 May; 159():33-9. PubMed ID: 26455893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
    Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
    J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Likeability and abuse liability of commonly prescribed opioids.
    Wightman R; Perrone J; Portelli I; Nelson L
    J Med Toxicol; 2012 Dec; 8(4):335-40. PubMed ID: 22992943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
    Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomes.
    Babalonis S; Comer SD; Jones JD; Nuzzo P; Lofwall MR; Manubay J; Hatton KW; Whittington RA; Walsh SL
    Psychopharmacology (Berl); 2021 Sep; 238(9):2503-2514. PubMed ID: 34106317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.
    Walsh SL; Nuzzo PA; Lofwall MR; Holtman JR
    Drug Alcohol Depend; 2008 Dec; 98(3):191-202. PubMed ID: 18606504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of Drug Liking in Abuse Potential Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales.
    Setnik B; Roland CL; Pixton G; Webster L
    J Clin Pharmacol; 2017 Feb; 57(2):266-274. PubMed ID: 27444046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D; Kopecky EA; Passik S; Shram MJ
    J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.
    Hanna M; O'Brien C; Wilson MC
    Eur J Pain; 2008 Aug; 12(6):804-13. PubMed ID: 18262450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.
    Cooper ZD; Bedi G; Ramesh D; Balter R; Comer SD; Haney M
    Neuropsychopharmacology; 2018 Sep; 43(10):2046-2055. PubMed ID: 29463913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
    Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
    Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
    J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
    Raleigh MD; Accetturo C; Pravetoni M
    J Pharmacol Exp Ther; 2020 Sep; 374(3):392-403. PubMed ID: 32586850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Psychopharmacology (Berl); 2003 Nov; 170(3):242-254. PubMed ID: 12955305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.